US brain-computer-interface startup Paradromics is quickly establishing itself as a major player in the neural-device space, ...

Neurotechnology company Paradromics will test its device in a trial aimed at safely restoring speech for people with severe motor impairments.

The Austin-based startup will test its high-bandwidth device to help restore speech in people with extremely limited movement.

The ALS Network, in partnership with 12 ALS United member organizations, announces the selection of its 2025 Research Innovation Grantees—an accomplished group of scientists and clinicians whose work ...

AstraZeneca’s Alexion division has received FDA approval for Koselugo (selumetinib) to treat adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on strong ...